crispr rais million conduct clinic trial increas
crispr issu million share rais gross proce
million estim crispr hold pro forma cash million advanc
industri lead therapeut pipelin crispr partner vertex
initi phase i/ii studi ex vivo transfusion-depend beta-th patient
germani multipl clear europ beta-th sickl cell diseas
scd expect fda could clear ind hold year importantli crispr
remain on-track file ind allogen allogen crispr-modifi
car-t look first-ev crispr data next year drive share higher
reiter overweight rate increas price target
account recent deal roll forward discount period
phase i/ii underway germani ex vivo crispr therapi
could prove cur beta-thalassemia scd crispr initi phase i/ii
studi beta-thalassemia patient clinic site germani
expect addit clinic start multipl accept europ
beta-thalassemia scd expect fda clear ind scd
first-in-man data next year serv import driver set
potenti rapid approv beta-th scd vertex co-develop
indic project global sale beta-th billion
scd billion
crispr car-t approach clinic crispr develop pipelin allogen
crispr-edit car-t product compani plan file ind target
could also see ind file car-t candid target
bcma multipl myeloma target solid tumor
see opportun signific valu creation crispr car-t pipelin
valid partnership octob crispr sign allianc vertex
co-develop six crispr therapi includ preclin cystic fibrosi
program addit crispr bayer form joint ventur casebia develop
crispr therapi sever combin immunodefici scid hemophilia
congenit heart diseas crispr sign partnership viacyt edit immune-
suppress properti pancreat progenitor cell type diabet expect
crispr enter addit innov gene edit partnership
technolog unproven may fail man crispr involv
patent litig could advers effect compani abil conduct busi
compani like requir futur capit
crsp pioneer develop therapeut genom edit
proj ev net cash
debt total capit
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
first crispr studi open enrol germani
expect ind car-t
crispr pioneer develop gene edit technolog first
describ semin paper scienc founder dr emmanuel charpenti
system make precis cut dna immens therapeut potenti crispr
gene edit compani start ex vivo cell therapi view smart
approach lower technic risk enabl product optim prior reintroduct
disrupt patient hematopoiet stem cell hsc induc fetal
hemoglobin hbf express potenti cure hemoglobinopathi beta-thalassemia
sickl cell diseas scd multipl clear europ crispr partner
vertex pharmaceut tenthoff initi first phase i/ii studi
transfusion-depend beta-th patient germani first-in-man data next year
import mileston crispr entir field anticip acceler approv
beta-th europ global sale billion
summer fda place hold ind scd believ clinic
hold indic new concern rather repres fda exercis greater scrutini first-
ever clinic trial crispr therapi anticip fda clear ind
crispr could initi phase i/ii scd trial year present expect acceler approv
scd global sale billion
crispr also appli engin allogen car-t importantli crispr
retain ownership immune-oncolog program lead candid advantag
current autolog car-t off-the-shelf therapi conveni
administr crispr file ind target bcma multipl
myeloma target renal cell carcinoma ind next two car-t
expect see opportun signific valu creation crispr car-t pipelin
cripsr activ partner technolog expand therapeut develop
maxim sharehold valu notabl vertex allianc sign octob six
crispr therapi includ preclin cystic fibrosi program addit crispr
bayer form joint ventur casebia develop crispr therapi sever combin
immunodefici scid hemophilia congenit heart diseas recent crispr sign
partnership viacyt edit immune-suppress properti pancreat progenitor cell
type diabet expect crispr enter addit innov gene edit partnership
crispr cross-licens ip intellia howev current patent disput
edita februari patent trial appeal board ptab declar
interfer issu broad prokaryot patent pend berkley eukaryot
patent decis affirm court appeal earlier month see ip
disput complic call multipl patent disput sever territori
last week crispr issu million share rais gross proce million
estim crispr hold pro forma cash million fund oper
first beta-thalassemia patient treat phase i/ii studi year
potenti fda clearanc ind scd
file ind allogen car-t
report first-in-man data phase i/ii beta-th scd
file ind anti-bcma
page
reiter overweight rate increas price target roll
forward discount period factor recent offer price target
base increas project enterpris valu billion billion
valu beta-thalassemia billion million appli
standard multipl ebitda million discount back
valu sickl cell diseas billion million appli
standard multipl ebitda million discount
multipl standard higher margin ebitda profit share
valu million million appli standard
multipl sale million discount back continu
valu bcma allogen car-t million also
continu valu crispr portion casebia joint ventur million
add project cash million prior cash million
divid estim billion market cap million share previous million
follow recent offer arriv revis price target
page
hemoglobinopathi
beta-thalassemia inherit hemoglobin disord affect estim patient
world-wide endem certain region north africa middl east part asia due
mutat hemoglobin patient experi lower level hemoglobin dysfunct
abnorm protein circul prevent adequ oxygen tissu spontan
natur mutat produc heterogen gene variant vari sever main type
thalassemia either alpha beta name underli chain mutat
beta-thalassemia result mutat one beta globin gene classifi three
type diseas thalassemia major character two copi mutat homozyg
beta-globin gene caus absenc beta-globin patient sever diseas
hemoglobin essenti non-funct requir continu blood transfus thalassemia
intermedia occur patient one copi variant heterozyg two copi
mutat intermedia less sever form diseas major may need regular blood
transfus requir frequent monitor thalassemia minor least sever form
diseas patient carri one copi gene variant yet asymptomat world
sickl cell diseas scd anoth inherit hemoglobin disord like beta-thalassemia
result mutat beta-globin gene scd patient retain two normal copi alpha-
globin mutat beta-globin caus abnorm hemoglobin hb gene
inherit either homozyg patient scd heterozyg patient
consid sickl cell trait
red blood cell rbc carri oxygen throughout bodi healthi rbc disc-shap
pliabl facilit transport microvasculatur abnorm hb form elong rope-lik
fiber result distort crescent sickl shape sickle-shap
rbc rigid less abl squeez micro-capillari result sickl cell
microvasculatur caus blockag obstruct decreas
microvascular blood flow mbf therebi cut oxygen suppli result tissu necrosi
result ischemia caus pain episod call vaso-occlus crisi voc
primari complic scd common caus hospit buchanan et al biol blood
marrow transplant suppl howev time repeat episod
necrosi caus organ damag sever morbid voc occasion result acut chest
syndrom ac occur blockag lung caus death
estim american afflict scd preval sickl cell trait
approxim african american rate higher caribbean reach high
certain region africa cdc result emigr high preval
geographi scd grow may underestim europ
main stay therapi beta-thalassemia blood transfus major intermedia
patient along iron chelat therapi howev treatment-rel complic lack
complianc rise cost pressur beta-thalassemia care approach
morbid mortal rate report order signific organ
complic present diseas burden patient age srivastava et al haematologica
page
hydroxyurea shown util prophylaxi decreas number voc fact clinic data
demonstr reduct voc episod decreas transfus depend agraw
et al indian hematol blood transfu treat voc hydrat pain
manag standard care despit treatment option scd substanti worsen
adulthood begin organ complic increas morbid mortal scd patient
live beyond year least half demonstr irrevers organ damag least one organ
shorten live due result organ damag
hematopoiet stem cell transplant hsct present cur therapi patient
beta-thalassemia scd howev hsct limit due challeng find suitabl
donor harsh precondit high risk transplant mortal graft-v -host diseas
gvhd patient access hsct also restrict due endem natur diseas certain
asian african countri cost hsct associ care feasibl mani
countri lack suffici train clinic center facil safe conduct hsct
last year privately-held emmau receiv fda approv endari l-glutamin powder treat
children adult scd first approv scd therapi year endari
reduc number sickl cell crise versu patient placebo week
treatment also reduc hospit durat hospit stay time first crisi although
approv potenti meaning patient dearth therapeut option believ recent
advanc gene therapi gene edit scd hold promis potenti cur outcom
increas express fetal hemoglobin hbf becom attract gene edit approach
treat beta-hemoglobinopathi rational support infant scd high level
hbf less sever phenotyp includ reduc rate acut pain episod less
frequent ac howev number hbf express erythrocyt declin age
constitut less adult pleas exhibit rapid declin circul
hbf erythrocyt occur earli month age rare condit call hereditari persist
fetal hemoglobin hpfh occur patient entir switch hbf hba studi
shown scd beta-thalassemia patient hpfh less sever asymptomat
diseas despit high hb express improv diseas attribut hbf reduc
polymer deoxygen hb addit hbf result hybrid tetram alpha beta
gamma-globin sickl rbc akinshey et al blood
transit hbf hba erythrocyt express develop
page
attract target abil modul hbf express mediat transit
gamma-globin beta-globin transcript produc protein repress hbf
gene express develop therefor inhibit express hold therapeut
potenti restor hbf express genome-wid associ studi elucid singl
nucleotid polymorph snp locu correl hbf express adult
variant associ beta-thalassemia uda et al pna
scd lettr et al pna
crispr lead candid autolog ex vivo gene-edit therapi
disrupt increas hbf express symptomat patient beta-thalassemia
scd patient hsc harvest expos disrupt erythroid
enhanc locat chromosom upstream gene prevent express repress
transcript factor restor gamma-globin express symptomat patient pleas
exhibit singl gene transfer increas hbf erythrocyt circul
mechan action
crispr report gene correct express data includ patient sampl
oral present product gamma-globin mrna protein observ
significantli higher rate bi-allel edit vs mono-allel edit healthi donor
cell compar control bi-allel edit uniqu featur
import enhanc therapeut effect gene edit result edit translat
express hbf level therapeut requir potenti cure patient
edit symptomat beta-thalassemia patient hematopoiet stem cell demonstr
higher ratio gamma beta globin express alpha-globin express compar
carrier level scd patient sampl also show higher gamma-globin mrna protein
express rel total gamma-globin beta-globin express high rate edit effici
observ long-term hsc throughout differenti affect engraft rate
edit effici support scale gmp product clinic use importantli highli
select effici edit hematopoiet stem cell target site
sever beta-thalassemia scd clear europ earlier
month crispr partner vertex announc clinic site germani open enrol
single-arm phase i/ii studi beta-thalassemia expect first patient
dose studi enrol transfusion-depend td beta-thalassemia non
compound heterozyg -thalassemia latter popul typic less sever
page
diseas less frequent transfus enrol heterozyg patient also differenti
crispr clinic strategi bluebird bio van buren treatment sever
patient although patient enrol crispr studi requir
units/year transfus prior year view
impedi daili life
administ singl iv infus follow myeloabl condit
busulfan first two patient receiv undergo serial safeti follow-up
period multipl site enrol addit patient could get first-in-man
data
follow posit preliminari data crispr may expand studi enrol patient
compani could regist approv primari endpoint proport subject
achiev transfus reduct least month month period follow singl
infus secondari endpoint clinic signific includ achiev transfus
independ month month cell engraft hbf product safeti believ
crispr request break design like seek acceler approv
bluebird set regulatori preced beta-thalassemia scd compani develop
lentivir gene therapi lentiglobin treat td beta-thalassemia sever scd ema
grant lentiglobin acceler assess treat td beta-thalassemia patient
submiss patient expect eha bluebird report
lentiglobin patient achiev transfusion-independ correl vector number copi level
hemoglobin product data report global phase northstar
studi updat expect decemb sever
relat crispr believ bluebird clinic meaning result form preced
acceler approv base small patient size fact bluebird one first compani
file ema condit approv adapt pathway pilot program bluebird
expect file base northstar studi td beta-th patient
heterozyg phenotyp second phase i/ii studi sever scd td beta-
thal patient also support approv mean lentiglobin condit european approv
would base patient primari endpoint transfus independ least
month lentiglobin infus key focu regul
initi first-in-man phase i/ii trial germani initi data next year
anticip crispr expand enrol phase i/ii studi potenti file
global regul patient base assumpt anticip acceler
approv beta-th europ asia expect
use primarili thalassemia major intermedia patient consid
could prove potenti cur regimen thu reduc total elig popul cure
patient subsequ year earli make price assumpt ahead clinic
data present anticip price per cure
europ equival asia project peak annual penetr
 europ asia
forecast sale million million grow million
project european sale million million grow
million project asian sale million million grow
million total forecast global beta-thalassemia sale million
million grow billion pleas exhibit
page
global sale forecast beta-thalassemia
crispr vertex file ind scd april support first-in-man phase i/ii
trial summer fda place hold ind applic believ
clinic hold repres new concern rather increas scrutini part fda
first-ev crispr clinic studi believ crispr abl address outstand issu
ind ultim clear year expect first scd patient could
treat single-arm phase i/ii studi
posit data anticip crispr expand single-arm phase i/ii studi enrol
approxim patient serv basi registr continu anticip
acceler approv scd europ assum
crispr would like requir partner commerci africa middl east
india largest scd market assum use sever scd
patient consid could prove potenti cur regimen thu reduc
total elig popul cure patient subsequ year anticip price
per year europ project
peak annual penetr europ
forecast sale million million grow billion
project european sale million million grow
million total forecast global scd sale million
million grow billion pleas exhibit page
page
 european sale forecast scd
page
unit cell anemia treat annual penetr per sale cell anemia treat annual penetr per sale sale car-t therapi
car-t therapi remain one excit area cancer research patient physician
investor larg pharma august gilead van buren acquir kite
billion cash follow celgen celg raymond acquisit juno billion cash
januari london-bas autolu autl cover rais million ipo june
cover file rais million upcom ipo
novarti kymriah tisagenlecleucel kite yescarta axicabtagen ciloleucel
target car-t therapi receiv fda approv treat rare b-cell hematolog malign
last month kymriah also receiv ema approv first approv car-t cell therapi
europ excit regulatori success base high respons rate even
cur result patient novarti kymriah produc respons rate
relapsing/relaps refractori pediatr acut lymphoblast leukemia kite/gilead
yescarta achiev durabl respons rate adult relapsed/refractori larg b-cell
kymriah yescarta valid therapeut target hematolog malign
marker b-cell differenti primari mediat b-cell receptor bcr
signal express normal cell upregul malign b-cell
major b-cell malign includ type b-cell lymphoma type b-cell
leukemia highli express offer promis target diseas intervent wang et al
perhap larger challeng associ recent approv autolog car-t manufactur
highli refractory/relaps popul patient may deterior even die wait
treatment logist issu aris clinic site conduct cell collect storag
differ manner may result inconsist therapeut composit end process
autolog cell therapi manufactur expens result high cog manufactur
pass price therapi kymriah price yescarta
per patient cost includ precondit hospital-bas patient care
expens high price tag face reimburs push back payor high
price limit access potenti cur car-t therapi cancer patient need
crispr retain ownership allogen car-t program
allogen product harvest healthi donor-deriv t-cell cultur modifi ex
vivo engin car-t product multiplex use make knock-out
knock-in edit car-t specif use disrupt t-cell receptor tcr
function insert trac locu homology-direct repair edit
trac locu shown uniform express enhanc t-cell potenc tumor site
well reduct risk gvhd elimin gene ablat express
hla-i molecul prevent t-cell mediat cell kill enhanc persist
car-t cell knocking-out reduc immuno-suppress tumor
microenviron crispr achiev edit effici tripl knockout
/car quadrupl knockout lead program
target car-t pleas exhibit effici rate multiplex edit improv
sinc prior updat process also maintain ratio edit event
disrupt immun respons allogen manufactur also scalabl lower
manufactur cost facilit administr patient current autolog car-t
page
multiplex edit effici car-t
crispr demonstr vivo activ lymphoma mous model
last mice treat achiev high kill rate leukem blast b-
model surviv raji tumor model base potent vivo activ crispr
initi ind-en studi expect ind file look
phase i/ii all-com b-cell malign studi start
page
data posit anticip crispr could file global regul
fda acceler approv b-cell malign includ nhl cll
assum use late stage relapsed/refractori patient anticip
price in-lin kymriah project peak penetr nhl
cll forecast sale million million
grow million pleas exhibit
 sale forecast b-cell malign
crispr advanc preclin allogen car-t candid addit ind file
plan vitro data present exhibit consist edit effici
multiplex gene edit bcma consist crispr-
mediat edit process could facilit expans allogen car-t pipelin vivo data
also show potenc singl inject multipl myeloma renal cell
carcinoma mous model complet inhibit tumor growth day anticip crispr
file ind begin clinic studi next year
page
ventur bayer
octob crispr enter collabor vertex option exclus licens
six novel therapeut crispr receiv million front vertex made million
equiti invest compani vertex exercis first option treat beta-
thalassemia scd crispr recogn million defer revenu
partner share develop commerci cost upon commerci
crispr book revenu vertex book ex-u sale global net profit
share equal among partner
non-hemoglobinopathi target in-licens vertex pay futur mileston
million per target upon commerci crispr elig royalti global net sale rang
single-digit low teen one disclos preclin program gene correct
product treat cystic fibrosi
decemb crispr bayer form joint ventur call casebia develop
crispr therapi treat blood disord blind congenit heart diseas casebia
specif focus develop vivo applic disclos hemophilia
sever combin immunodefici diseas scid first two indic crispr
contribut ip bayer contribut fund million up-front
period made commit contribut addit million fund oper bayer also
made million equiti invest crispr ipo crispr bayer interest
casebia parti design two vote seat casebia board dr jame burn ph
appoint ceo novemb prior join recent head sanofi
juli crispr privat form collabor develop novel t-cell
therapi neon develop person therapeut focus neoantigen vaccin
autolog t-cell therapi partner combin area expertis gener potent t-cell
therapi direct neoantigen term deal undisclos
septemb crispr partner viacyt privat combin gene edit regen
medicin co-develop pancreat progenitor cell treat type diabet one limit
approach requir immunosuppress therapi goal crispr collabor gene edit
immunosuppress properti cell line avoid system immunosuppress promot
engraft crispr edit may elimin need encaptur deliveri devic cell
could potenti cur type diabet crispr pay viacyt million front either
cash stock viacyt may elect receiv addit million convert note crispr
compani co-develop co-commerci cell therapi product
page
risk associ crispr common drug discoveri develop
compani includ clinic regulatori commerci risk specif crispr includ
technolog deliveri technolog novel technolog may fail man
crispr current engag patent litig could materi neg impact
compani abil busi unit state oncolog rare diseas highli
competit field larger better-fund player crispr may unabl file ind
crispr therapi may fail clinic gain regulatori approv mount pressur
drug price crispr may unabl charg premium price novel potenti cur
therapi compani may fail meet revenu project crispr may spend
budget may need rais addit capit exist collabor may fail
affect futur collabor revenu compani may unabl enter new
page
thousand except per share
research develop
gener administr
loss attribut non-controlling interest
dividend attribut convert prefer stock
net incom alloc particip secur
compani report piper jaffray estim
net loss includ one-tim dividend convert prefer stock class convert unit follow ipo
current disclosur inform compani found
